Comparative Pharmacology
Head-to-head clinical analysis: DEFERIPRONE versus EXJADE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFERIPRONE versus EXJADE.
DEFERIPRONE vs EXJADE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deferiprone is an iron chelator that binds to ferric iron (Fe3+) to form a stable complex, promoting iron excretion in urine. It reduces iron overload in tissues and prevents iron-induced free radical damage.
Deferasirox is an oral iron chelator that binds iron with high affinity in a 2:1 ratio. It promotes excretion of iron primarily in the feces via bile, reducing total body iron stores.
75 mg/kg/day orally in three divided doses (maximum 3 g/day).
20-40 mg/kg orally once daily, titrated based on serum ferritin trends, maximum 40 mg/kg per day.
None Documented
None Documented
2-3 hours (terminal elimination half-life). Due to its short half-life, multiple daily doses are required to maintain therapeutic chelation; levels decline rapidly after dose cessation.
Clinical Note
moderateMagnesium sulfate + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium salicylate + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Magnesium salicylate."
Clinical Note
moderateIron sucrose + Deferiprone
"The serum concentration of Deferiprone can be decreased when it is combined with Iron sucrose."
Clinical Note
moderateIron + Deferiprone
Terminal elimination half-life is 8–16 hours, supporting once-daily dosing.
Primarily renal excretion as iron complex (ferrioxamine) and unchanged drug; 70-90% of a dose is recovered in urine within 24 hours, predominantly as the iron chelate. Less than 10% is eliminated in feces via biliary excretion.
Primarily fecal (84% of total clearance), with ~8% renal (as unchanged drug and metabolites).
Category C
Category C
Iron Chelator
Iron Chelator
"The serum concentration of Deferiprone can be decreased when it is combined with Iron."